Abstract
Context: Low 25-hydroxyvitamin D [25(OH)D] and high PTH may contribute to increased mortality risk in older adults. Objective: The aim of the study was to test the association between 25(OH)D, PTH, and mortality in older men. Design and Setting: The prospective Osteoporotic Fractures in Men (MrOS) study was conducted at six U.S. clinical centers. Participants: We studied community-dwelling men at least 65 yr old (n = 1490). Main Outcome Measure: Multivariate-adjusted proportional hazards models estimated the hazard ratio (HR) for mortality; cause of death was classified as cancer, cardiovascular, and other by central review of death certificates. Results: During 7.3 yr of follow-up, 330 (22.2%) participants died: 97 from cancer, 110 from cardiovascular disease, and 106 from other causes. The adjusted HR per SD decrease in 25(OH)D for all-cause mortality was 1.01 (95% CI, 0.89, 1.14); no association between 25(OH)D and cardiovascular or other-cause mortality was seen. Unexpectedly, lower 25(OH)D levels were modestly associated with a decreased risk of cancer mortality (adjusted HR per SD decrease, 0.80; 95% CI, 0.64, 0.99). Analyzing 25(OH)D as a categorical variable did not alter these results. Higher PTH levels (log-transformed) were associated with an increased risk of all-cause mortality (adjusted HR per SD increase, 1.15; 95% CI, 1.03, 1.29) and cardiovascular mortality (adjusted HR per SD increase in PTH, 1.21; 95% CI, 1.00, 1.45). Conclusions: In contrast to previous studies, lower 25(OH)D levels were not associated with an increased risk of all-cause or cause-specific mortality in older men. Higher PTH levels were associated with a modest increase in mortality risk.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4625-4634 |
| Number of pages | 10 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 95 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2010 |
Bibliographical note
Funding Information:The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health (NIH) funding. The National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute on Aging, the National Center for Research Resources, and the NIH Roadmap for Medical Research provide support under the following grant numbers: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01AR45583, U01 AG18197, U01-AG027810, and UL1 RR024140 . The NIH had no direct role in the design and conduction of the study; collection, management, analysis, and interpretation of data; or preparation, review, or approval of the manuscript.
Funding Information:
Disclosure Summary: The authors have nothing to declare; all are funded by NIH grants as mentioned above in the support footnote.
